Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of RO7812653 in early symptomatic Alzheimer's disease
NL-OMON60584Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of RO7812653 in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Feb 2026; status: completed.
02
Drugs
RO7812653
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60584.